Get the Stockscreener App
1.70
7.10%
-0.13
Pre-market:
1.98
0.28
+16.47%
Acumen Pharmaceuticals Inc stock is traded at $1.70, with a volume of 228.62K.
It is down -7.10% in the last 24 hours and down -24.44% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.83
Open:
$1.81
24h Volume:
228.62K
Relative Volume:
0.88
Market Cap:
$102.14M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.5179
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-8.11%
1M Performance:
-24.44%
6M Performance:
-25.11%
1Y Performance:
-60.92%
1-Day Range:
$1.70
$1.81
1-Week Range:
$1.70
$1.95
52-Week Range:
$1.69
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.70 | 102.14M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian
Acumen's Alzheimer's Drug Shows Promise: Phase 1 Trial Reveals Strong Safety Profile, Plaque Reduction - StockTitan
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Purchased by Geode Capital Management LLC - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Bought by Barclays PLC - Defense World
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock - Investing.com India
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 Shares - MarketBeat
Matt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals CEO sells shares worth $87,873 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CEO sells shares worth $87,873 - Investing.com
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock - Investing.com
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock - Investing.com
Reviewing Acumen Pharmaceuticals (NASDAQ:ABOS) & argenx (NASDAQ:ARGX) - Defense World
State Street Corp Has $1.28 Million Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.71 amid market challenges - Investing.com Nigeria
ABOS stock touches 52-week low at $1.71 amid market challenges By Investing.com - Investing.com South Africa
Acumen stock touches 52-week low at $1.9 amid market challenges - Investing.com Australia
The Manufacturers Life Insurance Company Lowers Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
ABOS stock touches 52-week low at $2.08 amid market challenges - Investing.com Australia
ABOS stock touches 52-week low at $2.08 amid market challenges By Investing.com - Investing.com South Africa
Contrasting Acumen Pharmaceuticals (NASDAQ:ABOS) and Genetic Technologies (NASDAQ:GENE) - Defense World
I-Mab Leads Our Spotlight On 3 US Penny Stocks - Simply Wall St
Comparing MiNK Therapeutics (NASDAQ:INKT) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Halozyme to Present at Upcoming Investor Conferences - Finansavisen
ABOSAcumen Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times
Acumen Pharmaceuticals to Present Alzheimer's Treatment Progress at Evercore Conference | ABOS Stock News - StockTitan
HC Wainwright Has Bearish Estimate for ABOS FY2024 Earnings - MarketBeat
Analyzing Ginkgo Bioworks (NYSE:DNA) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Aurora Cannabis Inc. (NASDAQ:ACB) Sees Large Increase in Short Interest - Defense World
HC Wainwright Reiterates “Buy” Rating for Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Catalent, Inc. (NYSE:CTLT) Shares Sold by Farther Finance Advisors LLC - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given Buy Rating at HC Wainwright - MarketBeat
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress - Investing.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress By Investing.com - Investing.com UK
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic - TipRanks
Acumen Pharmaceuticals' Shares Drop on Wider 3Q Loss - MarketWatch
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Acumen Reports $258.9M Cash Runway Despite Widening Q3 Loss; Alzheimer's Trial Advances | ABOS Stock News - StockTitan
Earnings Scheduled For November 12, 2024 - Benzinga
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at Stifel Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharma announces new appointment | Biotechnology | The Pharmaletter - The Pharma Letter
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 03 '25 |
Sale |
1.84 |
11,122 |
20,506 |
97,745 |
| Barton Russell | Chief Operating Officer |
Jan 03 '25 |
Sale |
1.86 |
7,636 |
14,225 |
89,231 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 03 '25 |
Sale |
1.84 |
13,235 |
24,367 |
198,210 |
| Siemers Eric | Chief Medical Officer |
Jan 03 '25 |
Sale |
1.85 |
10,859 |
20,047 |
106,717 |
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):